SCHEMBL14507174

SCHEMBL14507174

COc1ccc(OC(=O)Nc2cc3c4c(cccc4c2)C(=O)N(CCN(C)C)C3=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FTO Q9C0B1 3/20 0.61
▸ CYP2D6 P10635 1/20 0.54
▸ HEXA P06865 6/20 0.54
▸ HEXB P07686 6/20 0.54
▸ PABPC1 P11940 1/20 0.51
▸ KDM4E B2RXH2 4/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ PLK1 P53350 1/20 0.47
▸ RAD52 P43351 2/20 0.47
▸ NR1I2 O75469 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ AHR P35869 1/20 0.47
▸ RCE1 Q9Y256 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ CLTC Q00610 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14507173 0.90 FTO (0.62) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL5466175 0.87 FTO (0.60) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL11447427 0.84 FTO (0.66) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL11440392 0.83 FTO (0.71) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL4188839 0.82 FTO (0.70) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL11435202 0.80 HEXA (0.71) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL14507176 0.79 FTO (0.75) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL5270794 0.79 FTO (0.69) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL5267061 0.79 FTO (0.67) FTOCYP2D6HEXAHEXBPABPC1
SCHEMBL13707320 0.79 FTO (0.61) FTOCYP2D6HEXAHEXBPABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070117836-A1 NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM UNIBIOSCREEN S.A. (BE) 2007-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117836-A1 NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM NPM1, NAPRT, NUTF2 FTO 3049/4885CYP2D6 62/4885HEXA 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback